AP4 (Iclusig 45 mg)
Generic Name: ponatinib
Pill imprint AP4 has been identified as Iclusig 45 mg.
Iclusig is used in the treatment of chronic myelogenous leukemia; acute lymphoblastic leukemia and belongs to the drug classes BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iclusig 45 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- 45 mg
- Prescription only
- Drug Class:
- BCR-ABL tyrosine kinase inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- ARIAD Pharmaceuticals, Inc.
More about Iclusig (ponatinib)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.